[go: up one dir, main page]

CA2205442A1 - Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants - Google Patents

Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants

Info

Publication number
CA2205442A1
CA2205442A1 CA002205442A CA2205442A CA2205442A1 CA 2205442 A1 CA2205442 A1 CA 2205442A1 CA 002205442 A CA002205442 A CA 002205442A CA 2205442 A CA2205442 A CA 2205442A CA 2205442 A1 CA2205442 A1 CA 2205442A1
Authority
CA
Canada
Prior art keywords
nsaid
composition
higher plants
hydrocolloid gum
gum obtainable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002205442A
Other languages
French (fr)
Other versions
CA2205442C (en
Inventor
David R. Friend
Karen Yu
Jagdish Parasrampuria
Eric H. Kuhrts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Development AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2205442A1 publication Critical patent/CA2205442A1/en
Application granted granted Critical
Publication of CA2205442C publication Critical patent/CA2205442C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An oral-delivery pharmaceutical composition for reducing the gastric irritation effect of an NSAID in the upper GI tract of a mammal. The composition includes (a) a mucosal protective amount of a pharmaceutically-acceptable hydrocolloid gum obtainable from higher plants, (b) a dispersion-enhancing amount of another excipient and (c) a therapeutically-effective amount of an NSAID. Also disclosed is a process for preparing the composition and a method for reducing the gastric irritation effect of the NSAID by administering the composition. Also, disclosed is a composition particularly useful for preparing an aqueous suspension.
CA002205442A 1994-12-01 1995-11-30 Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants Expired - Fee Related CA2205442C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34760194A 1994-12-01 1994-12-01
US08/347,601 1994-12-01
PCT/US1995/015599 WO1996016639A1 (en) 1994-12-01 1995-11-30 Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants

Publications (2)

Publication Number Publication Date
CA2205442A1 true CA2205442A1 (en) 1996-06-06
CA2205442C CA2205442C (en) 2003-01-21

Family

ID=23364417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205442A Expired - Fee Related CA2205442C (en) 1994-12-01 1995-11-30 Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants

Country Status (8)

Country Link
EP (1) EP0804169A4 (en)
JP (1) JPH10509982A (en)
AU (1) AU690417B2 (en)
CA (1) CA2205442C (en)
FI (1) FI972305A0 (en)
MX (1) MX9704079A (en)
NO (1) NO972485L (en)
WO (1) WO1996016639A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
AU695734B2 (en) * 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
ATE316782T1 (en) * 1998-08-21 2006-02-15 Novartis Pharma Gmbh NEW ORAL FORMULATIONS FOR 5-HT4 AGONISTS OR ANTAGONISTS
SE0003125D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (en) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmaceutical molded body
WO1986006627A1 (en) * 1985-05-15 1986-11-20 Riker Laboratories, Inc. Sustained release theophylline compositions and processes
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
JP2628231B2 (en) * 1992-12-30 1997-07-09 エフ エム シー コーポレーション Konjac glucomannan readily available as a release-controlling excipient

Also Published As

Publication number Publication date
JPH10509982A (en) 1998-09-29
NO972485L (en) 1997-07-31
FI972305L (en) 1997-05-30
WO1996016639A1 (en) 1996-06-06
EP0804169A1 (en) 1997-11-05
FI972305A0 (en) 1997-05-30
AU4595196A (en) 1996-06-19
EP0804169A4 (en) 1998-08-19
MX9704079A (en) 1997-12-31
NO972485D0 (en) 1997-05-30
CA2205442C (en) 2003-01-21
AU690417B2 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
AU7939298A (en) An itraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
CA2149362A1 (en) Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid
AU7921887A (en) Therapeutic agents
RO116342B1 (en) Oral liquid pharmaceutical composition
AU584154B2 (en) Pharmaceutical preparations in the form of instant granules or tablets, and process for their manufacture
AU7549696A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
WO2001076575A3 (en) The treatment of respiratory diseases
EP0202819A3 (en) A delivery system for an active ingredient and a process for preparation thereof
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
CA2076744A1 (en) Viral Agent Associated with Mystery Swine Disease
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
CA2093282A1 (en) Intraoral medicament-releasing device
AU4297089A (en) Dispersable formulation of diclofenac in free acid form
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
CA2256751A1 (en) Coated trimebutine maleate tablet
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
CA2205442A1 (en) Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
AU3756797A (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
AU3743295A (en) Colchicine derivatives and the therapeutical use thereof
AU5655696A (en) Pharmaceutical composition containing acetylcysteine, carboc ysteine or erdosteine in combination with a beta 2 agonist a nd an expectorant for the treatment of respiratory tract dis orders
CA2033418A1 (en) Pharmaceutical preparation for oral administration in fluid form
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed